Mandating a Boost to Pfizer’s Bottom Line

Posted On Jul 28, 2021 By Addison Wiggin

The COVID vaccines have been great for drug companies’ bottom lines. Today Pfizer said it sold $7.8 billion worth of shots in the second quarter… with a total of $33.5 billion in sales expected by year-end. The company also stressed once again that everyone might need a third dose of its product to stave off the delta variant. Needless to say, mandating a third jab would boost Pfizer’s profits even higher… which makes it easy to question the drugmaker’s motives. Ray Blanco admits it’s a concern. At the same time, he says, “there’s a lot of misinformation” about exactly how the vaccines really work.

Subscribe to Platinum Reserve Today!

From blue chips to penny stocks, income plays to growth opportunities, commodities to techs, ETFs to OTCs, bonds to options — the Agora Financial Platinum Reserve covers it all. You simply cannot find a more comprehensive source of investment analysis and recommendations.

Subscribe Today!